Titlebook: Top Articles in Primary Care; John Russell,Neil S. Skolnik Book 2023 The Editor(s) (if applicable) and The Author(s), under exclusive lice

只看該作者 · 發(fā)表于 2025-3-25 09:46:22

the chronological order of publication. Each article reviewed includes a succinct overview of methodology and the results, followed by a discussion that puts the results into clinical context.? All articles ar978-3-031-25619-6978-3-031-25620-2

只看該作者 · 發(fā)表于 2025-3-25 12:17:53

只看該作者 · 發(fā)表于 2025-3-25 19:09:57

只看該作者 · 發(fā)表于 2025-3-25 20:35:32

只看該作者 · 發(fā)表于 2025-3-26 03:30:34

Thrombolysis in Acute Strokes (ECASS-II)-1998ith a clot dissolver called tissue plasminogen activator (TPA) [1]. The ECASS II trial was one of the first trials to review the safety and efficacy of alteplase (recombinant TPA) which to this day is still one of the first line therapies for ischemic CVA.

只看該作者 · 發(fā)表于 2025-3-26 05:20:51

只看該作者 · 發(fā)表于 2025-3-26 11:18:58

只看該作者 · 發(fā)表于 2025-3-26 12:44:27

只看該作者 · 發(fā)表于 2025-3-26 19:21:17

Empagliflozin in Diastolic Heart Failure (EMPEROR)-2021unction, among other pathophysiologic abnormalities [1]. Multiple trials in patients with HFpEF have failed to reach their primary endpoints. The EMPEROR-PRESERVED trial is the first trial to have reach its primary outcome in patients with HFpEF.

		自動(dòng)登錄	找回密碼
密碼			To register

關(guān)于派博傳思			派博傳思旗下網(wǎng)站			友情鏈接
派博傳思介紹	公司地理位置	論文服務(wù)流程	影響因子官網(wǎng)	吾愛論文網(wǎng)	大講堂	北京大學(xué)	Oxford Uni.	Harvard Uni.
發(fā)展歷史沿革	期刊點(diǎn)評(píng)	投稿經(jīng)驗(yàn)總結(jié)	SCIENCEGARD	IMPACTFACTOR	派博系數(shù)	清華大學(xué)	Yale Uni.	Stanford Uni.
\|Archiver\|手機(jī)版\|小黑屋\| 派博傳思國(guó)際 ( 京公網(wǎng)安備110108008328) GMT+8, 2025-10-13 13:38
Copyright © 2001-2015 派博傳思京公網(wǎng)安備110108008328 版權(quán)所有 All rights reserved